- Home
- CBNA vs DERM Comparison
CBNA vs DERM Comparison
Compare CBNA & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNA
- DERM
- Stock Information
- Founded
- CBNA 2006
- DERM 2014
- Country
- CBNA United States
- DERM United States
- Employees
- CBNA N/A
- DERM 58
- Industry
- CBNA
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- CBNA
- DERM Health Care
- Exchange
- CBNA NYSE
- DERM Nasdaq
- Market Cap
- CBNA 133.2M
- DERM 93.8M
- IPO Year
- CBNA 2024
- DERM 2021
- Fundamental
- Price
- CBNA $24.31
- DERM $4.48
- Analyst Decision
- CBNA Buy
- DERM Strong Buy
- Analyst Count
- CBNA 3
- DERM 3
- Target Price
- CBNA $27.67
- DERM $9.50
- AVG Volume (30 Days)
- CBNA 32.5K
- DERM 97.6K
- Earning Date
- CBNA 02-15-2025
- DERM 11-12-2024
- Dividend Yield
- CBNA N/A
- DERM N/A
- EPS Growth
- CBNA 135.51
- DERM N/A
- EPS
- CBNA 4.49
- DERM N/A
- Revenue
- CBNA $49,968,000.00
- DERM $57,771,000.00
- Revenue This Year
- CBNA N/A
- DERM N/A
- Revenue Next Year
- CBNA N/A
- DERM $36.49
- P/E Ratio
- CBNA $5.34
- DERM N/A
- Revenue Growth
- CBNA 76.01
- DERM N/A
- 52 Week Low
- CBNA $20.10
- DERM $2.85
- 52 Week High
- CBNA $27.56
- DERM $8.00
- Technical
- Relative Strength Index (RSI)
- CBNA N/A
- DERM 30.68
- Support Level
- CBNA N/A
- DERM $4.40
- Resistance Level
- CBNA N/A
- DERM $5.19
- Average True Range (ATR)
- CBNA 0.00
- DERM 0.25
- MACD
- CBNA 0.00
- DERM -0.07
- Stochastic Oscillator
- CBNA 0.00
- DERM 1.85
About CBNA CHAIN BRIDGE BANCORP INC
Chain Bridge Bancorp Inc is engaged in banking industry. It offers commercial and personal banking services, including deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.